Thermo Fisher Scientific Inc. (TMO) Shares Sold by Oppenheimer & Co. Inc.
Oppenheimer & Co. Inc. cut its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.9% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 83,735 shares of the medical research company’s stock after selling 748 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Thermo Fisher Scientific were worth $15,843,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Horan Capital Advisors LLC. grew its holdings in shares of Thermo Fisher Scientific by 2.3% during the 3rd quarter. Horan Capital Advisors LLC. now owns 18,124 shares of the medical research company’s stock worth $3,429,000 after purchasing an additional 410 shares during the period. Sivik Global Healthcare LLC boosted its holdings in Thermo Fisher Scientific by 80.0% during the 3rd quarter. Sivik Global Healthcare LLC now owns 45,000 shares of the medical research company’s stock valued at $8,514,000 after acquiring an additional 20,000 shares during the period. Barrett Asset Management LLC boosted its holdings in Thermo Fisher Scientific by 7.8% during the 3rd quarter. Barrett Asset Management LLC now owns 101,620 shares of the medical research company’s stock valued at $19,227,000 after acquiring an additional 7,335 shares during the period. Oakworth Capital Inc. boosted its holdings in Thermo Fisher Scientific by 332.1% during the 3rd quarter. Oakworth Capital Inc. now owns 1,145 shares of the medical research company’s stock valued at $214,000 after acquiring an additional 880 shares during the period. Finally, Bronfman E.L. Rothschild L.P. boosted its holdings in Thermo Fisher Scientific by 9.9% during the 3rd quarter. Bronfman E.L. Rothschild L.P. now owns 2,987 shares of the medical research company’s stock valued at $565,000 after acquiring an additional 268 shares during the period. Institutional investors and hedge funds own 86.16% of the company’s stock.
Thermo Fisher Scientific Inc. (NYSE:TMO) traded up $1.53 during mid-day trading on Tuesday, reaching $189.49. The company’s stock had a trading volume of 1,423,700 shares, compared to its average volume of 1,564,405. The company has a quick ratio of 0.81, a current ratio of 1.26 and a debt-to-equity ratio of 0.85. The firm has a market cap of $75,371.09, a price-to-earnings ratio of 20.66, a P/E/G ratio of 1.72 and a beta of 1.06. Thermo Fisher Scientific Inc. has a 52 week low of $139.88 and a 52 week high of $201.20.
Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.24 by $0.07. The company had revenue of $5.12 billion for the quarter, compared to analyst estimates of $5.03 billion. Thermo Fisher Scientific had a return on equity of 15.94% and a net margin of 11.73%. Thermo Fisher Scientific’s revenue for the quarter was up 13.9% compared to the same quarter last year. During the same quarter last year, the company earned $2.03 EPS. equities analysts anticipate that Thermo Fisher Scientific Inc. will post 9.36 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Monday, January 15th. Shareholders of record on Friday, December 15th will be given a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 0.32%. The ex-dividend date of this dividend is Thursday, December 14th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.19%.
TMO has been the subject of a number of research analyst reports. Cowen restated a “buy” rating and set a $200.00 target price on shares of Thermo Fisher Scientific in a report on Friday, September 1st. Argus restated a “buy” rating on shares of Thermo Fisher Scientific in a report on Tuesday, August 22nd. They noted that the move was a valuation call. Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $208.00 target price for the company in a report on Thursday, September 7th. Goldman Sachs Group initiated coverage on Thermo Fisher Scientific in a report on Tuesday, September 26th. They set a “buy” rating and a $225.00 target price for the company. Finally, Deutsche Bank set a $226.00 target price on Thermo Fisher Scientific and gave the company a “buy” rating in a report on Thursday, October 26th. One investment analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $205.21.
In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 50,000 shares of the stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $188.39, for a total value of $9,419,500.00. Following the sale, the chief executive officer now owns 252,577 shares of the company’s stock, valued at approximately $47,582,981.03. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.49% of the stock is owned by company insiders.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with Analyst Ratings Network's FREE daily email newsletter.